Shire PLC talked about the rapid progress of integrating Baxalta Inc., including an increased projection of cost savings, and how it wants to build an ophthalmology franchise around recently approved Xiidra at the Bank of America Merrill Lynch Global Healthcare Conference 2016, Sept. 14-16 in London. Meanwhile, Sanofi discussed the challenges of Toujeo formulary placement in the US and what it's looking for in M&A after missing out on Medivation Inc., while Amgen Inc. highlighted its expectations for osteoporosis candidate romosozumab.
These are heady times for Shire with the late June closing of its Baxalta acquisition, followed by the approval in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?